New hope for ALS patients: experimental drug CNM-Au8 now available through expanded access

NCT ID NCT06408727

TEMPORARILY_NOT_AVAILABLE Disease control Sponsor: Clene Nanomedicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program provides early access to an experimental drug called CNM-Au8 for people with amyotrophic lateral sclerosis (ALS), a progressive nerve disease. Participants must be 18 or older and have a confirmed ALS diagnosis. The goal is to offer treatment to those who cannot join other clinical trials, while researchers gather more safety data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis Papillon-Lefevre disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS AMYOTROPHIC LATERAL SCLEROSIS PALS

Contacts and locations

Locations

Columbia Unniversity

New York, New York, 10032, United States
Duke University

Durham, North Carolina, 27704, United States
Northwestern University

Chicago, Illinois, 60611, United States
Nova Southeastern University

Fort Lauderdale, Florida, 33328, United States
Pennsylvania State University

Hershey, Pennsylvania, 17033, United States
Synapticure

Chicago, Illinois, 60613, United States
Texas Neurology

Dallas, Texas, 75206, United States
University of Iowa

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.